The second patient was a 50-year-old woman affected by refractory congestive heart failure due to a post-ischaemic adverse LV remodelling leading to severe functional mitral valve regurgitation with a tethering of posterior mitral leaflet. Six months before, the patient was treated with primary percutaneous coronary intervention (PCI) of left anterior descending artery for a late presentation myocardial infarction with concomitant chronic total occlusion of the right coronary artery. An arrhythmic storm and haemodynamic instability occurred during primary PCI requiring mechanical circulatory support with IABP. At 1 month, after cardiac magnetic resonance imaging showed no residual myocardial viability with an LVEF of 0.18, the patient received an implantable cardioverter-defibrillator. In the following months, the patient was severely symptomatic for dyspnoea (NYHA functional Class IV). Considering the high risk for surgical mitral repair (STS score 7.5%), no need for further revascularization or ventriculoplasty as patient was not considered a candidate for open-heart surgery/heart transplantation, after Heart Team discussion, the patient was planned for MitraClip implantation. The pre-intervention TTE/TOE evaluation confirmed a severe systolic dysfunction (LVEF 0.18), atrial enlargement, diastolic dysfunction, and pulmonary hypertension. Transoesophageal echocardiography showed degenerative leaflets and tethering of the posterior mitral valve leaflet, no evidence of flail leaflets and multiple MR jets between A2-P1 and A2-P3 scallops (). After multidisciplinary discussion, the procedure of PMVR was planned with advanced LV assistance by Impella CP. Similar to previous case, Impella CP implantation was performed with a transfemoral approach, after transseptal puncture and heparinization. A single MitraClip XTR was successfully delivered. Device time including PMVR and Impella CP implantation was 47 min ( and and ). Impella CP was weaned at the end of the procedure and the haemostasis performed by two pre-implanted suture devices (Perclose Proglide; Abbott, Santa Clara, CA, USA). The final TOE/TTE demonstrated an optimal result with residual mild mitral regurgitation (). No complications occurred. In-hospital course was uneventful and the patient was discharged 5 days after index procedure. At 1- and 6-month follow-up, the patient showed an optimal clinical compensation, improvement of symptoms, and functional class (NYHA functional Class II). Transthoracic echocardiography evaluation showed an LVEF of 0.31 (end-diastolic volume: 178 mL; end-systolic volume: 122 mL); a trivial residual mitral regurgitation with an average diastolic gradient of 2 mmHg; an increase stroke volume from 30 to 40 mL; a persistent severe tricuspid regurgitation without pulmonary hypertension evaluated by pulmonary artery acceleration time.
The first patient is a 72-year-old woman with severe LV dysfunction related to idiopathic dilated cardiomyopathy leading to heart failure [New York Heart Association (NYHA) function Class IV] despite optimal medical therapy and cardiac resynchronization therapy. She was referred to our tertiary centre due to recurrent rehospitalizations for refractory heart failure. After a first phase of pharmacological treatment or haemodynamic compensation, transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE) evaluation confirmed a severely dilated ventricle (LV end-diastolic diameter: 78 mm) associated with a severe LV dysfunction [LV ejection fraction (LVEF): 0.22]. A severe functional mitral regurgitation was revealed (effective regurgitant orifice area: 0.35 cm2, vena contracta: 0.7 cm) due to tethering of the leaflets resulting in multiple jet, the major between A2 and P3 (). The calculated Society of Thoracic Surgeon (STS) score was 8.7%. After Heart Team discussion, transcatheter intervention with MitraClip implantation was planned with advanced LV mechanical circulatory support of Impella CP. The procedure was performed as usual under TOE guidance and general anaesthesia. The Impella CP was inserted, immediately after transseptal puncture and heparinization, through left femoral artery and positioned across the aortic valve with a flow rate of 3 L/min ( and ). Despite the TOE imaging noise generated by the coaxial pump, a MitraClip XTR was successfully implanted (). The final TTE/TOE, with Impella CP running at the lowest performance level, demonstrated an optimal result with residual mild mitral regurgitation with an average diastolic gradient of 2 mmHg and peak diastolic gradient of 5 mmHg (). The entire procedure was performed with Impella CP assistance, which guaranteed the LV unload during the procedure. Device time including PMVR and Impella CP implantation was 38 min. Impella CP support was left in place and active. In the following hours, progressive improvement of the patient’s haemodynamic performance occurred and Impella CP support was weaned until the removal of the device. Haemostasis was guaranteed by two pre-implanted suture closure devices (Perclose Proglide; Abbott, Santa Clara, CA, USA). In-hospital course was uneventful and the patient was discharged 6 days after the index procedure with good haemodynamic compensation.\nAt 1- and 6-month follow-up, the patient showed improved symptoms and functional class (NYHA functional Class II). The TTE evaluation showed an improvement of LV systolic function (LVEF 0.27) and confirmed the post-procedural result showing a residual mild mitral regurgitation (regurgitant volume of 12 mL).